VHA Home HealthCare

genesispharma.com

GENESIS Pharma started its activity in pharmaceutical biotechnology in 1997, at a time when the industry was still at an early development stage, not only in Greece but also in Europe. The company's goal was to combine the rapid progress in science with a successful and innovative business venture, thus paving the way for the creation of a new market. Working with consistency and dedication to this end, GENESIS Pharma became the first Greek pharmaceutical company specializing in the promotion, sales and distribution of biopharmaceutical products and is currently the largest by turnover among Greek companies focusing on innovative branded medicines.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

JUBILANT HOLLISTERSTIER LLC ENTERS INTO COOPERATIVE AGREEMENT OF $149.6 MN WITH US GOVERNMENT TO EXPAND CRITICAL VACCINE MANUFACTURING CAPACITY

Jubilant Pharmova Limited | May 31, 2022

news image

Jubilant Pharmova Limited has announced today that Jubilant Pharma Limited, a wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based pharmaceutical contract manufacturer has entered into a cooperative agreement for $149.6 million (USD) with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) on behalf of th...

Read More

Business Insights

GLAUKOS LICENSES IVEENA’S INVESTIGATIONAL KERATOCONUS THERAPY

iVeena and Glaukos | August 25, 2022

news image

iVeena Delivery Systems Inc. a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transplantation in the United States. IVMED-80 is a...

Read More

Pharmacy Market

TC BIOPHARM BEGINS DOSING PHASE 2B CLINICAL STUDY EVALUATING ITS LEAD COMPOUND, OMNIMMUNE®, IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

TC BioPharm | November 23, 2022

news image

TC Biopharm a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced the dosing of its first three patients within its Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia. The initial 5 patients in the trial are deemed a "safety cohort", spaced two weeks apart with safety review by an oversight board to confirm no drug related toxic...

Read More

Business Insights

ITERATIVE SCOPES RECEIVES FDA CLEARANCE FOR AI-ASSISTED POLYP DETECTION DEVICE SKOUT™

Iterative Scopes | September 23, 2022

news image

Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance. SKOUT, a real-time computer-aided polyp detection device developed by Iterative Scopes, uses advanced computer vision technolog...

Read More
news image

Pharmacy Market

JUBILANT HOLLISTERSTIER LLC ENTERS INTO COOPERATIVE AGREEMENT OF $149.6 MN WITH US GOVERNMENT TO EXPAND CRITICAL VACCINE MANUFACTURING CAPACITY

Jubilant Pharmova Limited | May 31, 2022

Jubilant Pharmova Limited has announced today that Jubilant Pharma Limited, a wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based pharmaceutical contract manufacturer has entered into a cooperative agreement for $149.6 million (USD) with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) on behalf of th...

Read More
news image

Business Insights

GLAUKOS LICENSES IVEENA’S INVESTIGATIONAL KERATOCONUS THERAPY

iVeena and Glaukos | August 25, 2022

iVeena Delivery Systems Inc. a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transplantation in the United States. IVMED-80 is a...

Read More
news image

Pharmacy Market

TC BIOPHARM BEGINS DOSING PHASE 2B CLINICAL STUDY EVALUATING ITS LEAD COMPOUND, OMNIMMUNE®, IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

TC BioPharm | November 23, 2022

TC Biopharm a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced the dosing of its first three patients within its Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia. The initial 5 patients in the trial are deemed a "safety cohort", spaced two weeks apart with safety review by an oversight board to confirm no drug related toxic...

Read More
news image

Business Insights

ITERATIVE SCOPES RECEIVES FDA CLEARANCE FOR AI-ASSISTED POLYP DETECTION DEVICE SKOUT™

Iterative Scopes | September 23, 2022

Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance. SKOUT, a real-time computer-aided polyp detection device developed by Iterative Scopes, uses advanced computer vision technolog...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us